Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)
Sequential Administration of Docetaxel/Gemcitabine Followed by Concurrent Chemo-radiotherapy, With or Without Consolidation Chemotherapy, as First Line Treatment in Patients With Unresectable Stage IIIA/IIIB NSCLC. A Randomized Phase II Study
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Alexandroupolis、希腊
- University General Hospital of Alexandroupolis, Dep of Medical Oncology
-
Athens、希腊
- 401 Military Hospital, Medical Oncology Unit
-
Athens、希腊
- Air Forces Military Hospital, Dep of Medical Oncology
-
Athens、希腊
- Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases
-
Athens、希腊
- IASO General Hospital of Athens, 1st Dep of Medical Oncology
-
Athens、希腊
- Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine
-
Athens、希腊
- Sotiria General Hospital, 1st, 3rd, 6th, 7th, 8th Dep of Pulmonary Diseases
-
Piraeus、希腊
- Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology
-
Thessaloniki、希腊
- Theagenion Anticancer Hospital of Thessaloniki
-
-
Crete
-
Heraklion、Crete、希腊、71110
- University Hospital of Crete
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- histologically or cytologically confirmed, unresectable locally advanced (stage IIIA/IIIB) NSCLC
- no previous therapy for NSCLC is allowed
- age >18 years
- bidimensionally measurable disease
- performance status (WHO) 0-2
- absence of pleural effusion
- adequate liver (serum bilirubin < 1.5 times the upper normal limit (UNL); AST and ALT < 2.5 times the UNL in the absence of demonstrable liver metastases, or < 5 times the UNL in the presence of liver metastases); adequate renal function (serum creatinine < 1.5 times the UNL); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function
- life expectancy of more than 3 months
- written informed consent
Exclusion Criteria:
- active infection
- history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)
- malnutrition (loss of ≥ 20% of the original body weight)
- performance status: 3-4
- sensor or motor neuropathy > grade I
- second primary malignancy, except for non-melanoma skin cancer
- psychiatric illness or social situation that would preclude study compliance
- pregnant or lactating women
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:1
DG -> RT
|
Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
其他名称:
Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
其他名称:
After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy. During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32
Docetaxel 75mg/m2 IV on day 1 for 3 cycles
其他名称:
|
实验性的:2
DG -> RT -> DCarbo
|
Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
其他名称:
Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
其他名称:
After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy. During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32
Docetaxel 75mg/m2 IV on day 1 for 3 cycles
其他名称:
Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Time to tumor progression (TTP)
大体时间:1 year
|
1 year
|
次要结果测量
结果测量 |
大体时间 |
---|---|
毒性
大体时间:每个化疗周期的毒性评估
|
每个化疗周期的毒性评估
|
生活质量
大体时间:每两个周期评估一次
|
每两个周期评估一次
|
反应速度
大体时间:通过 CT 或 MRI 确认的客观反应(第 3 和第 6 个周期)
|
通过 CT 或 MRI 确认的客观反应(第 3 和第 6 个周期)
|
Overall survival
大体时间:Probability of 1-year survival (%)
|
Probability of 1-year survival (%)
|
Symptom improvement
大体时间:Assessment every two cycles
|
Assessment every two cycles
|
合作者和调查者
调查人员
- 首席研究员:Vassilis Georgoulias, MD、University Hospital of Crete
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.